Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment

Annales d'Endocrinologie

Volumn 73, Issue 3, 2012, Pages 225-229

  Philippon, Melanie ^a   Morange, Isabelle ^a   Barrie, Marilyne ^a   Barlier, Anne ^a   Taieb, David ^a   Dufour, Henry ^a   Conte Devolx, Bernard ^a   Brue, Thierry ^a   Castinetti, Frédéric ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROLACTIN; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HUMAN; HYPOPHYSIS APOPLEXY; LONG TERM CARE; LUMBAR PUNCTURE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROLACTIN BLOOD LEVEL; PROLACTINOMA; STEREOTACTIC RADIOSURGERY; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; DOPAMINE AGONISTS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERPROLACTINEMIA; HYPOPHYSECTOMY; HYPOPITUITARISM; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION, MISSENSE; NEOPLASM RECURRENCE, LOCAL; OPHTHALMOPLEGIA; PANCREATIC NEOPLASMS; PARATHYROID NEOPLASMS; PITUITARY APOPLEXY; PITUITARY NEOPLASMS; PROLACTIN; PROTO-ONCOGENE PROTEINS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SPINAL NEOPLASMS;

EID: 84863850783     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.03.001     Document Type: Article

References (19)

1. Heaney A.P. Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 2011, 96:3649-3660.
2. Kaltsas G.A., Nomikos P., Kontogeorgos G., Buchfelder M., Grossman A.B. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005, 90:3089-3099.
3. Pernicone P.J., Scheithauer B.W., Sebo T.J., Kovacs K.T., Horvath E., Young W.F., et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 1997, 79:804-812.
4. Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 2009, 12:256-260.
5. Fadul C.E., Kominsky A.L., Meyer L.P., Kingman L.S., Kinlaw W.B., Rhodes C.H., et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006, 105:621-626.
6. Hagen C., Schroeder H.D., Hansen S., Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009, 161:631-637.
7. Lim S., Shahinian H., Maya M.M., Yong W., Heaney A.P. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006, 7:518-520.
8. Murakami M., Mizutani A., Asano S., Katakami H., Ozawa Y., Yamazaki K., et al. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 2011, 68:E1761-E1767.
9. Losa M., Mazza E., Terreni M.R., McCormack A., Gill A.J., Motta M., et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 2010, 163:843-851.
10. Yung W.K., Albright R.E., Olson J., Fredericks R., Fink K., Prados M.D., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.
11. Bush Z.M., Longtine J.A., Cunningham T., Schiff D., Jane J.A., Vance M.L., et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 2010, 95:E280-E290.
12. Raverot G., Sturm N., de Fraipont F., Muller M., Salenave S., Caron P., et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010, 95:4592-4599.
13. Kovacs K., Scheithauer B.W., Lombardero M., McLendon R.E., Syro L.V., Uribe H., et al. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 2008, 115:261-262.
14. McCormack A.I., McDonald K.L., Gill A.J., Clark S.J., Burt M.G., Campbell K.A., et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009, 71:226-233.
15. Goudet P., Bonithon-Kopp C., Murat A., Ruszniewski P., Niccoli P., Menegaux F., et al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the groupe d'etude des tumeurs endocrines. Eur J Endocrinol 2011, 165:97-105.
16. Marini F., Falchetti A., Del Monte F., Carbonell Sala S., Gozzini A., Luzi E., et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 2006, 1:38.
17. Scheithauer B.W., Kovacs K., Nose V., Lombardero M., Osamura Y.R., Lloyd R.V., et al. Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. Hum Pathol 2009, 40:270-278.
18. Theodoropoulou M., Cavallari I., Barzon L., D'Agostino D.M., Ferro T., Arzberger T., et al. Differential expression of menin in sporadic pituitary adenomas. Endocr Relat Cancer 2004, 11:333-344.
19. Loeffler J.S., Shih H.A. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011, 96:1992-2003.